SCTC21C
Phase 3Biologic
SCTC21C is one of 127 biologic programs targeting Amyloidosis. It is currently in Phase 3.
4
Indications
4
Total Trials
4
Active Trials
126
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
258 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
TALVEY
Johnson & JohnsonPhase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Etentamig
AbbViePhase 3
Velcade
TakedaPhase 3
Opioid
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCTC21C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- SSinocelltech Ltd.